undamentalytics Newsletter
Sign in

Lakefront Biotherapeutics NV (LKFT) stock

Add to watchlist

Add holding +

NASDAQ: LKFT Nasdaq Biotechnology Next results ~November 11, 2026

A Fundamentals grade

Lakefront Biotherapeutics NV is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$59

Valuation models combined (2)

Base case. Range ~$52–$73. Weighted average of 2 models (price-to-earnings vs peers, revenue-to-maturity model), the price-to-earnings vs peers counting double.

Price vs value

No Buy/Hold/Sell rating is issued: only 2 valuation models apply; a rating needs 3.

Lakefront Biotherapeutics NV valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds34 adding, 49 cuttingOf 16 active managers that changed their stake, 7 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Lakefront Biotherapeutics NV files

Where Lakefront Biotherapeutics NV stands after its latest Filing

Revenue for the twelve months was $1.26bn, up 321.6% on a year earlier, faster than the 15.0% growth a quarter earlier. That growth ranks 19 of 172 among the biotechnology companies we cover. Free-cash-flow margin rose to -24.4% from -238.1% a year earlier. Operating margin widened to 26.5% from -73.2%. Against its peers on growth, profitability, cash generation and balance sheet, it grades A. It passes 3 of our 3 financial-health checks. Our valuation models combined value is $60.16 a share, against a share price of $32.28.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Lakefront Biotherapeutics NV's trailing-twelve-month revenue grew 321.6% year on year, with a free-cash-flow margin of -24.4%. Where it stands out: days sales outstanding of 7 days ranks 4 of 100 biotechnology companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to 321.6% (+306.6pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 321.6% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 306.6 points higher than a quarter earlier.
  • High operating margin. 26.5% of revenue is left as operating profit, against a median of -189.4% for biotechnology companies we cover.
  • Margins widening. Operating margin is up 94.9 points on a year ago.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Burning cash. Free cash flow was -24.4% of revenue over the last 12 months.
  • Weak cash conversion. Free cash flow was -85% of net income over the last 12 months.

Latest results

Earnings per share
$0.03 against an average estimate of -$11.50: beat by 100.3%
Next report
November 11, 2026

Lakefront Biotherapeutics NV's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.8%
  • 1 week+1.0%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$1.3B
Operating margin
26.5%
Net margin
28.9%
EPS (TTM, diluted)
$5.51

Growth

Revenue growth
+321.6%
Change in growth rate
+306.6 pts
Share count change
+0.0%

Cash

Free cash flow (TTM)
-$307M
FCF margin
-24.4%
Stock pay % of revenue
2.2%

News & updates

Updated November 2, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for LKFT from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Lakefront Biotherapeutics NV valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 2 valuation models apply; a rating needs 3.

Valuation models

We value Lakefront Biotherapeutics NV as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. ~$52 ~$45–$120 Primary model, counts double
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$15 ~$9.3–$25 Left out: far from the other models (more than 3x away from their median)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity below long-run growth
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$73 ~$58–$92 Included
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: earnings are positive: price-to-earnings is the better measure
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$59 ~$52–$73 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Lakefront Biotherapeutics NV with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026, after the close.

Analysts' consensus

No analyst estimates are published for Lakefront Biotherapeutics NV: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$11.50 $0.03 +100.3%
Mar 2026 −$0.97 $0.21 +121.6%
Dec 2025 −$0.07 $12.27 +17634.6%
Sept 2025 −$0.28 −$0.18 +37.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Nov 2026
Buy233%
Hold350%
Sell117%

Monthly trend

  1. Nov 202611316
  2. Oct 202611316
  3. Sep 20261416

Counts of recommendations published by analysts covering Lakefront Biotherapeutics NV, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.5%
of tradable shares
Days to cover
3.95
at average volume
Short interest, 1 month
−59%
to October 15, 2026
Held by institutions
24%
of shares
Held by insiders
25.4%
of shares
Employees
196
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Lakefront Biotherapeutics NV in five measures

Fundamentals grade A
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Lakefront Biotherapeutics NV
$0 $500M $1B $1.5B FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY15 Q4: $43.9M Revenue (TTM), FY16 Q4: $143.4M Revenue (TTM), FY17 Q4: $143.6M Revenue (TTM), FY18 Q4: $329.3M Revenue (TTM), FY19 Q4: $934.6M Revenue (TTM), FY20 Q4: $545.5M Revenue (TTM), FY21 Q4: $277.3M Revenue (TTM), FY22 Q4: $254.1M Revenue (TTM), FY23 Q4: $259.3M Revenue (TTM), FY24 Q4: $298.3M Revenue (TTM), FY25 Q4: $1.3B $1.3B

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY15 Q4 $43.9M
FY16 Q4 $143.4M
FY17 Q4 $143.6M
FY18 Q4 $329.3M
FY19 Q4 $934.6M
FY20 Q4 $545.5M
FY21 Q4 $277.3M
FY22 Q4 $254.1M
FY23 Q4 $259.3M
FY24 Q4 $298.3M
FY25 Q4 $1.3B
Revenue growth, TTM YoY Lakefront Biotherapeutics NV
-100% 0% 100% 200% 300% 400% FY16 Q4 FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Revenue growth, TTM YoY, FY16 Q4: 226.7% Revenue growth, TTM YoY, FY17 Q4: 0.1% Revenue growth, TTM YoY, FY18 Q4: 129.3% Revenue growth, TTM YoY, FY19 Q4: 183.8% Revenue growth, TTM YoY, FY20 Q4: -41.6% Revenue growth, TTM YoY, FY21 Q4: -49.2% Revenue growth, TTM YoY, FY22 Q4: -8.3% Revenue growth, TTM YoY, FY23 Q4: 2.0% Revenue growth, TTM YoY, FY24 Q4: 15.0% Revenue growth, TTM YoY, FY25 Q4: 321.6% 321.6%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY16 Q4 226.7%
FY17 Q4 0.1%
FY18 Q4 129.3%
FY19 Q4 183.8%
FY20 Q4 -41.6%
FY21 Q4 -49.2%
FY22 Q4 -8.3%
FY23 Q4 2.0%
FY24 Q4 15.0%
FY25 Q4 321.6%
Operating margin (TTM) Lakefront Biotherapeutics NV
-300% -200% -100% 0% 100% FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Operating margin (TTM), FY15 Q4: -226.1% Operating margin (TTM), FY16 Q4: -8.9% Operating margin (TTM), FY17 Q4: -70.7% Operating margin (TTM), FY18 Q4: -16.9% Operating margin (TTM), FY19 Q4: 44.2% Operating margin (TTM), FY20 Q4: -37.4% Operating margin (TTM), FY21 Q4: -73.2% Operating margin (TTM), FY22 Q4: -54.3% Operating margin (TTM), FY23 Q4: -36.8% Operating margin (TTM), FY24 Q4: -68.3% Operating margin (TTM), FY25 Q4: 26.5% 26.5%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY15 Q4 -226.1%
FY16 Q4 -8.9%
FY17 Q4 -70.7%
FY18 Q4 -16.9%
FY19 Q4 44.2%
FY20 Q4 -37.4%
FY21 Q4 -73.2%
FY22 Q4 -54.3%
FY23 Q4 -36.8%
FY24 Q4 -68.3%
FY25 Q4 26.5%
FCF margin (TTM) Lakefront Biotherapeutics NV
-400% -200% 0% 200% 400% FY15 Q4 FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 FCF margin (TTM), FY15 Q4: -305.1% FCF margin (TTM), FY16 Q4: 181.4% FCF margin (TTM), FY17 Q4: -119.9% FCF margin (TTM), FY18 Q4: -54.9% FCF margin (TTM), FY19 Q4: 381.6% FCF margin (TTM), FY20 Q4: -98.3% FCF margin (TTM), FY21 Q4: -238.1% FCF margin (TTM), FY22 Q4: -218.8% FCF margin (TTM), FY23 Q4: -177.2% FCF margin (TTM), FY24 Q4: -122.2% FCF margin (TTM), FY25 Q4: -24.4% -24.4%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY15 Q4 -305.1%
FY16 Q4 181.4%
FY17 Q4 -119.9%
FY18 Q4 -54.9%
FY19 Q4 381.6%
FY20 Q4 -98.3%
FY21 Q4 -238.1%
FY22 Q4 -218.8%
FY23 Q4 -177.2%
FY24 Q4 -122.2%
FY25 Q4 -24.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Lakefront Biotherapeutics NV took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $1.3B
  2. Other income $29.2M · 2.3%
  3. Cost of revenue $33.6M · 2.7%
  4. Gross profit $1.2B · 97.3%
  5. Research and development $519M · 41.3%
  6. Other operating costs $371M · 29.5%
  7. Operating income $334M · 26.5%
  8. Net income $363M · 28.9%

Shares of revenue. Source: Lakefront Biotherapeutics NV's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained. Other income is income outside operations, such as investment gains.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 44 143 144 329 935 545 277 254 259 298 1,258
Gross profit — — — — — — 275 241 — 261 1,224
Operating income −99 −13 −101 −56 413 −204 −203 −138 −95 −204 334
Net income −131 60 −131 −35 168 −349 −122 −230 229 80 363
Diluted EPS −$3.68 $1.26 −$2.64 −$0.66 $2.79 −$5.35 −$1.87 −$3.50 $3.47 $1.21 $5.51
Growth (year on year)
Revenue — +226.7% +0.1% +129.3% +183.8% −41.6% −49.2% −8.3% +2.0% +15.0% +321.6%
Operating income — — — — — −149.4% — — — — —
Net income — — −318.6% — — −307.8% — — — −65.0% +352.6%
Diluted EPS — — −309.5% — — −292.0% — — — −65.1% +354.4%
Margins
Gross margin — — — — — — 99.3% 95.0% — 87.4% 97.3%
Operating margin −226.1% −8.9% −70.7% −16.9% 44.2% −37.4% −73.2% −54.3% −36.8% −68.3% 26.5%
Net margin −299.3% 41.7% −91.0% −10.5% 17.9% −63.9% −44.0% −90.4% 88.3% 26.9% 28.9%
Free-cash-flow margin −305.1% 181.4% −119.9% −54.9% 381.6% −98.3% −238.1% −218.8% −177.2% −122.2% −24.4%
Cash flow
Cash from operations −127 265 −166 −168 3,592 −488 −596 −527 −439 −346 −291
Capital spending 7 5 6 12 25 49 64 29 20 18 15
Free cash flow −134 260 −172 −181 3,567 −536 −660 −556 −459 −364 −307
Stock-based pay 6 12 19 32 43 91 84 93 61 22 27
Free cash flow after stock pay −140 248 −191 −212 3,524 −627 −744 −649 −521 −386 −334
Balance sheet
Cash 370 1,027 1,384 1,479 2,090 2,611 2,528 544 185 66 103
Total debt 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −370 −1,027 −1,384 −1,479 −2,090 −2,611 −2,528 −544 −185 −66 −103
Diluted shares 36m 47m 49m 52m 58m 65m 66m 66m 66m 66m 66m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 3 checks passed · December 31, 2025
What it owns · $4.0bn
Short-term assets $3.6bnLonger-term assets $384m
What it owes, and who funded it · $4.0bn
Short-term liabilities $179mLonger-term liabilities $21mShareholders' equity $3.8bn
  • Short-term assets cover short-term liabilities $3.6bn of assets due within a year against $179m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $3.6bn short-term assets against $21m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of $334m against $1m of interest.

From Lakefront Biotherapeutics NV's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
0.0%
year over year
R&D spending
41.3%
of revenue
Days sales outstanding
7 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated LKFT MDGL PTCT ACAD INSM LEGN Median
Revenue, last 12 months $1.3bn $1.3bn $1.2bn $1.1bn $1.5bn $1.0bn $56m
Revenue growth, last 12 months 321.6% 149.0% −35.1% 11.8% 240.0% 64.0% 12.6%
Revenue growth, 3-year average — — 13.1% 27.4% 75.6% — 13.7%
Revenue growth, latest quarter — 71.2% 69.6% 16.4% 268.4% — 10.2%
Gross margin 97.3% — 96.0% 91.1% 84.4% 61.4% 82.9%
Operating margin 26.5% −25.1% 12.8% 7.6% −37.1% −13.3% −189.4%
Operating margin, 3-year average −39.1% <−999% 13.8% 11.1% −179.0% — −363.5%
Net margin 28.9% −25.3% −9.2% 33.4% −39.9% −28.8% −169.8%
Cash from operations / revenue −23.1% −15.4% 0.9% 14.1% −39.2% −9.7% −168.0%
Free-cash-flow margin −24.4% −16.1% 0.2% 12.8% −41.3% −12.5% −162.4%
Free-cash-flow margin, 3-year average −127.4% <−999% 6.4% 0.8% −143.2% — −310.0%
Stock pay / revenue 2.2% 9.5% 7.7% 5.1% 11.0% — 20.0%
Change in share count 0.0% 14.8% 9.3% 3.0% 13.7% 0.8% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 321.6% 12.6% 19 of 172
Change in growth rate Growth +306.6pp -0.1pp 12 of 172
Gross margin Profitability 97.3% 82.4% 8 of 75
Operating margin Profitability 26.5% -189.4% 18 of 175
Net margin Profitability 28.9% -157.3% 19 of 180
Free-cash-flow margin Cash generation -24.4% -145.4% 55 of 176
Stock pay as % of revenue Cash generation 2.2% 19.2% 10 of 179
Change in share count Balance sheet 0.0% 7.9% 19 of 156
Days sales outstanding Balance sheet 7 days 75 days 4 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$960M
Institutions reporting
77
Shares held vs prior quarter
▲ 2.5%
Positions opened / closed
8 / 21

Top buyers and sellers, Q2 2026: 34 institutions bought and 49 sold ; the biggest buyer was Madison Avenue Partners, LP (+983K shares) and the biggest seller Segall Bryant & Hamill, LLC (−426K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Gilead Sciences, Inc. $500M 16.7M 52.1% 0.0%
Tang Capital Management LLC $114M 3.8M 11.8% 0.0%
Madison Avenue Partners, LP $103M 3.4M 10.8% ▲ 39.9%
Prosight Management, LP $61.3M 2.0M 6.4% ▲ 31.8%
Ecor1 Capital, LLC $50M 1.7M 5.2% 0.0%
Ameriprise Financial Inc $38.1M 1.3M 4.0% ▼ 10.7%
Dme Capital Management, LP $14.5M 483K 1.5% 0.0%
Renaissance Technologies LLC $12.2M 408K 1.3% ▲ 29.3%
Blackrock, Inc. $10.1M 338K 1.1% ▲ 8.3%
Point72 Asset Management, L.P. $8.1M 270K 0.8% ▼ 18.8%
D. E. Shaw & Co., Inc. $5.9M 198K 0.6% ▼ 8.3%
Millennium Management LLC $5.4M 181K 0.6% ▲ 67.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Lakefront Biotherapeutics NV's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Lakefront Biotherapeutics NV was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Lakefront Biotherapeutics NV in brief

What does Lakefront Biotherapeutics NV do?
Lakefront Biotherapeutics NV is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Lakefront Biotherapeutics NV's stock ticker?
Lakefront Biotherapeutics NV trades under the ticker LKFT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Lakefront Biotherapeutics NV's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Lakefront Biotherapeutics NV reported revenue of $1.3B, 321.6% higher than a year earlier, according to its SEC filings.
What is Lakefront Biotherapeutics NV's free cash flow?
Lakefront Biotherapeutics NV's free-cash-flow margin is -24.4% of revenue over the trailing twelve months, ranking 55 of the 176 biotechnology companies we cover.
Who are Lakefront Biotherapeutics NV's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Gilead Sciences, Inc., Tang Capital Management LLC and Madison Avenue Partners, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Who are Lakefront Biotherapeutics NV's competitors?
In our Biotechnology peer group, the companies closest to Lakefront Biotherapeutics NV are Madrigal Pharmaceuticals, Inc., PTC Therapeutics, Inc., Acadia Pharmaceuticals Inc, Insmed Inc and Legend Biotech Corp. The side-by-side comparison below sets their revenue, margins and growth against Lakefront Biotherapeutics NV's.
When is Lakefront Biotherapeutics NV's next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Lakefront Biotherapeutics NV announces its own schedule.